Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
What 5 Analyst Ratings Have To Say About Kimbell Royalty Partners
Analysts have provided the following ratings for Kimbell Royalty Partners (NYSE:KRP) within the last quarter:
Stephens & Co. Initiates Coverage On Kimbell Royalty Partners with Overweight Rating, Announces Price Target of $22
Stephens & Co. initiates coverage on Kimbell Royalty Partners (NYSE:KRP) with a Overweight rating and announces Price Target of $22.
Analyst Ratings for Kimbell Royalty Partners
Within the last quarter, Kimbell Royalty Partners (NYSE:KRP) has observed the following analyst ratings:
Kimbell Royalty Partners Q4 EPS $0.44 Beats $0.27 Estimate, Sales $55.68M Beat $47.55M Estimate
Kimbell Royalty Partners (NYSE:KRP) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.27 by 62.96 percent. This is a 126.51 percent increase over losses of $(1.66) per share
Kimbell Royalty Partners: Dividend Insights
Thursday marks the last chance for investors to receive the next dividend payout from Kimbell Royalty Partners.
Keybanc Maintains Overweight on Kimbell Royalty Partners, Raises Price Target to $17
Keybanc analyst Leo Mariani maintains Kimbell Royalty Partners (NYSE:KRP) with a Overweight and raises the price target from $16 to $17.
Wells Fargo Upgrades Kimbell Royalty Partners to Overweight, Raises Price Target to $18
Wells Fargo analyst Joseph McKay upgrades Kimbell Royalty Partners (NYSE:KRP) from Equal-Weight to Overweight and raises the price target from $15 to $18.
Kimbell Royalty Partners Reports Purchase Of Mineral, Royalty Interests For $57M In Cash
Expected to be immediately accretive to distributable cash flow per unit, diverse acquired acreage highlighted by over 26,000 gross producing wells and a core position in the Permian Basin, expected to increase run-rate